Myeloproliferative Neoplasms: Diagnosis and Treatment

TopicLeading institutions, researchers & key papers

This cluster of papers focuses on the molecular pathogenesis, diagnosis, treatment, and prognosis of myeloproliferative disorders such as polycythemia vera, essential thrombocythemia, and myelofibrosis. It covers topics such as JAK2 and CALR mutations, prognostic scoring systems, ruxolitinib therapy, hematologic response, leukemic transformation, and stem cell transplantation.

121

Works

IDs:OpenAlex

How has Myeloproliferative Neoplasms: Diagnosis and Treatment's publication output changed over time?

ScholarIQpublication output · 2006–2022

Output grew0% over the shown period — from 1 works in 2006 to 1 in 2022.

2006200720092010201520172018201920212022

What are the most-cited papers on Myeloproliferative Neoplasms: Diagnosis and Treatment?

ScholarIQmost cited works

Physiological Jak2V617F Expression Causes a Lethal Myeloproliferative Neoplasm with Differential Effects on Hematopoietic Stem and Progenitor Cells

Ann Mullally, Steven Lane, Brian Ball, Christine Megerdichian, Rachel Okabe, Fátima Al‐Shahrour, Mahnaz Paktinat, J. Erika Haydu, Elizabeth Housman, Allegra M. Lord, Gerlinde Wernig, Michael G. Kharas, Thomas Mercher, Jeffery L. Kutok, D. Gary Gilliland, Benjamin L. Ebert

S25671836. 2010395 CitationsOPEN ACCESS

SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor–Naïve Patients With Myelofibrosis

Ruben A. Mesa, Jean‐Jacques Kiladjian, John Catalano, Timothy Devos, Miklós Egyed, Andrzei Hellmann, Donal P. McLornan, Kazuya Shimoda, Elliott F. Winton, Wei Deng, Ronald L. Dubowy, Julia D. Maltzman, Francisco Cervantes, Jason Gotlib

Journal of Clinical Oncology. 2017375 CitationsOPEN ACCESS

Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I

Srđan Verstovšek, Ruben A. Mesa, Jason Gotlib, R. S. Levy, Vikas Gupta, John F. DiPersio, John Catalano, Michael W. Deininger, Carole B. Miller, Richard T. Silver, Moshe Talpaz, E. Winton, Jimmie H. Harvey, Murat O. Arcasoy, Elizabeth O. Hexner, Roger M. Lyons, Azra Raza, Kris Vaddi, William Sun, Wei Peng, V. Sandor, Hagop M. Kantarjian, For the COMFORT-I investigators

S2752781272. 2015331 CitationsOPEN ACCESS

Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders

Daniela Pietra, Sai Li, Angela Brisci, Francesco Passamonti, Elisa Rumi, Alexandre Theocharides, Maurizio Ferrari, Heinz Gisslinger, Róbert Královics, Laura Cremonesi, Radek C. Skoda, Mario Cazzola

Blood. 2007294 Citations

Gli1+ Mesenchymal Stromal Cells Are a Key Driver of Bone Marrow Fibrosis and an Important Cellular Therapeutic Target

Rebekka K. Schneider, Ann Mullally, Aurélien Dugourd, Fabian Peisker, Remco M. Hoogenboezem, Paulina M. H. van Strien, Eric M. Bindels, Dirk Heckl, Guntram Büsche, David Fleck, Gerhard Müller‐Newen, Janewit Wongboonsin, Mónica Ventura Ferreira, Victor G. Puelles, Julio Sáez-Rodríguez, Benjamin L. Ebert, Benjamin D. Humphreys, Rafael Kramann

S128124174. 2017268 CitationsOPEN ACCESS